CHEPLAPHARM closes financial year 2023 with record revenue and double-digit growth
EQS Group
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report
CHEPLAPHARM closes financial year 2023 with record..
EQS-News: Cheplapharm AG / Key word(s): Annual Results/Annual Report
CHEPLAPHARM closes financial year 2023 with record..
Sleep medications industry is projected to witness a CAGR of 6.8% during the period 2024-2032. This growth can be attributed to..
· Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market..